1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Vulvovaginal Candidiasis Global Clinical Trials Review, H2, 2016

Vulvovaginal Candidiasis Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Vulvovaginal Candidiasis Global Clinical Trials Review, H2, 2016" provides an overview of Vulvovaginal Candidiasis clinical trials scenario. This report provides top line data relating to the clinical trials on Vulvovaginal Candidiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Vulvovaginal Candidiasis Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2


Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Vulvovaginal Candidiasis to Infectious Disease Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Vulvovaginal Candidiasis to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Vulvovaginal Candidiasis Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Vulvovaginal Candidiasis 30
Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis 30
Aug 10, 2016: Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting 31
Aug 09, 2016: Cidara Therapeutics Announced Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting 31
Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis 32
Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors 32
Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016 33
Clinical Trial Profile Snapshots 35
Appendix 85
Abbreviations 85
Definitions 85
Research Methodology 86
Secondary Research 86
About GlobalData 87
Contact Us 87
Disclaimer 87
Source 88

List of Tables
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials by Region, 2016* 6
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Vulvovaginal Candidiasis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Vulvovaginal Candidiasis to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
Vulvovaginal Candidiasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Vulvovaginal Candidiasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Vulvovaginal Candidiasis to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17
Vulvovaginal Candidiasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Vulvovaginal Candidiasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Vulvovaginal Candidiasis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Vulvovaginal Candidiasis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Vulvovaginal Candidiasis to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
Vulvovaginal Candidiasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Vulvovaginal Candidiasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Vulvovaginal Candidiasis to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17
Vulvovaginal Candidiasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Vulvovaginal Candidiasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Vulvovaginal Candidiasis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Vulvovaginal Candidiasis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Vulvovaginal Candidiasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 86

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Proteinuria is a result of an excess of serum proteins in the urine, which can led to renal damage. The most common cause of proteinuria is diabetes. Globally, development the arena of proteomics and ...

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Endometriosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Endometriosis Industry

October 2016 $ 4950

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.